Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 Phase 1b in Overweight/Obese Non-Diabetic Subjects
NCT04855292Phase 1Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GX-G6 in obesity and Overweight (3 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Incidence and severity of adverse events up to 99 days. Started Jul 2021; status: completed.
02
Drugs
GX-G6
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04855292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855292.